Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Next Previous
Trial Profile

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Fludarabine; Granulocyte colony stimulating factor modulators; Granulocyte colony stimulating factor modulators; Hydroxycarbamide; Idarubicin; Mercaptopurine; Methotrexate; Methotrexate; Vincristine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZUMA-3
  • Sponsors Kite Pharma

Most Recent Events

  • 01 May 2025 Results assessing updated outcomes after >3 years median follow-up, published in the Leukemia.
  • 10 Dec 2024 Results (n=78) assessing clinical and pharmacokinetic/pharmacodynamic data in context of best response and durability of response, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 09 Dec 2024 Results presented in a Gilead Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top